Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008
- 12 November 2012
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 52 (5) , 941-949
Abstract
Background. Use of adjuvant chemotherapy for stage III colon cancer has increased since several trials have shown the beneficial effect on survival. In this population-based study we show time trends in the administration and costs of chemotherapy and relative survival of patients with stage III colon cancer. Methods. All patients surgically treated for adenocarcinoma of the colon stage III between 1990 and 2008 in The Netherlands were included. Relative survival (using period analyses) and Relative Excess Risks of death (RER) were calculated. The costs of chemotherapy were estimated. Results. A total of 24 111 colon cancer patients with stage III were included in the cohort. The administration (from 9.5% in 1990 to 61.8% in 2008; p < 0.001) and costs of chemotherapy (from €38 467 in 1990 to €3 876 150 in 2008) increased during the study period. Multivariable relative survival improved for patients receiving adjuvant chemotherapy (RER 0.93; 95% CI 0.92–0.94; p < 0.001). In contrast, relative survival remained stable for patients, younger than 80 years, who did not receive chemotherapy (RER 1.00; 95% CI 1.00–1.01; p = 0.3). Patients aged 80 years and older without chemotherapy, relative survival increased during the study period (RER 0.98; 95% CI 0.97–0.99; p < 0.001). Conclusions. The administration, the costs of chemotherapy and the survival of patients with stage III colon cancer increased over time. Whereas the costs and administration of chemotherapy increased extensively, relative survival increased to a lesser extent. For patients treated with adjuvant chemotherapy relative survival increased equally in all age groups.Keywords
This publication has 21 references indexed in Scilit:
- Use of Aspirin postdiagnosis improves survival for colon cancer patientsBritish Journal of Cancer, 2012
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJournal of Clinical Oncology, 2011
- Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patientsAnnals of Oncology, 2011
- Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006Annals of Oncology, 2010
- Treatment of the elderly colorectal cancer patient: SIOG expert recommendationsAnnals of Oncology, 2008
- Overcoming challenges associated with chemotherapy treatment in the senior adult populationCritical Reviews in Oncology/Hematology, 2008
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidityAnnals of Oncology, 2005
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990